(UroToday.com) The treatment landscape in advanced prostate cancer has rapidly evolved. In particular, agents with demonstrated survival benefits later in the natural history of prostate cancer have been used earlier in the disease process. In the context of metastatic castration resistant prostate cancer (mCRPC), docetaxel was the first agent to demonstrate a survival benefit when combined with conventional androgen deprivation therapy (ADT). Subsequently, docetaxel demonstrated benefit in metastatic hormone-sensitive prostate cancer (mHSPC), also referred to as metastatic castration-sensitive prostate cancer. Following this, a number of other treatment approaches have been assessed and are now clinically used including androgen receptor targeting agents, such as abiraterone acetate. Due to its mechanism of action, abiraterone acetate requires co-administration with an oral corticosteroid. Previous randomized control trials (RCTs) have shown increased cardiac risk with abiraterone acetate + androgen deprivation therapy (ADT).